1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy
(
- Contribution to journal › Article
- 2017
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
(
- Contribution to journal › Article
- 2013
-
Mark
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
(
- Contribution to journal › Article
- 2012
-
Mark
3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells
(
- Contribution to journal › Article
- 2009
-
Mark
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports
2009) Symposium on Expanding the Boundaries of Clinical Practice - Building an Experience with Targeted Therapies 20. p.25-31(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding